Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer

Purpose More than 99% of cervical cancers and up to 40% of vulvar cancers are human papillomavirus (HPV) related. HPV 16 and 18 are the most relevant subtypes. Novel technologies allow the detection of minimal amounts of circulating cell-free HPV DNA (ccfHPV-DNA). The aim of this study was to evalua...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-11, Vol.149 (14), p.12597-12604
Main Authors: Thangarajah, Fabinshy, Busshoff, Jana, Salamon, Janina, Pruss, Marie-Sandrine, Lenz, Caroline, Morgenstern, Bernd, Hellmich, Martin, Schlößer, Hans Anton, Lenz, Maximilian, Domröse, Christian, Mallmann, Michael R., Mallmann, Peter, Weiß, Jonathan, Franzen, Fabian, Merkelbach-Bruse, Sabine, Binot, Elke, Eich, Marie-Lisa, Büttner, Reinhardt, Schultheis, Anne Maria, Alidousty, Christina
Format: Article
Language:English
Subjects:
Biopsy
Cancer Research
Cervical cancer
Copy number
Deoxyribonucleic acid
DNA
Genital cancers
Hematology
Human papillomavirus
Internal Medicine
Medicine
Medicine & Public Health
Metastases
Oncology
Polymerase chain reaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose More than 99% of cervical cancers and up to 40% of vulvar cancers are human papillomavirus (HPV) related. HPV 16 and 18 are the most relevant subtypes. Novel technologies allow the detection of minimal amounts of circulating cell-free HPV DNA (ccfHPV-DNA). The aim of this study was to evaluate ccfHPV-DNA assessed by droplet digital PCR (ddPCR) as a biomarker for molecular therapy monitoring in early, advanced, relapsed and metastatic HPV-driven cervical and vulvar cancer. Methods Inclusion criteria of the study were histologically proven HPV 16/18-driven cervical and vulvar cancer with first diagnosed disease, newly diagnosed recurrence, or progression of disease. Blood samples were taken pre- and post-therapeutically. Circulating cell-free HPV DNA was quantified using ddPCR and the results were correlated with clinical data. Results The mean copy number of ccfHPV-DNA was 838.6 (± 3089.1) in pretreatment and 2.3 (± 6.4) in post-treatment samples ( p  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-023-05077-3